دورية أكاديمية
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
| العنوان: | Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024. |
|---|---|
| المؤلفون: | DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, Irving SA, Grannis SJ, Ong TC, Klein NP, Weber ZA, Reese SE, Ball SW, Barron MA, Naleway AL, Dixon BE, Essien I, Bride D, Natarajan K, Fireman B, Shah AB, Okwuazi E, Wiegand R, Zhu Y, Lauring AS, Martin ET, Gaglani M, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker M, Mohamed A, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Chang SY, Mallow C, Kwon JH, Exline MC, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Casey JD, Chappell JD, Grijalva CG, Swan SA, Johnson C, Lewis NM, Ellington S, Adams K, Tenforde MW, Paden CR, Dawood FS, Fleming-Dutra KE, Surie D, Link-Gelles R |
| مؤلفون مشاركون: | CDC COVID-19 Vaccine Effectiveness Collaborators |
| المصدر: | MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 29; Vol. 73 (8), pp. 180-188. Date of Electronic Publication: 2024 Feb 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Atlanta, GA : U.S. Centers for Disease Control Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control. |
| مواضيع طبية MeSH: | COVID-19 Vaccines* , COVID-19*/epidemiology , COVID-19*/prevention & control, Adult ; Humans ; Adolescent ; Advisory Committees ; Emergency Service, Hospital ; Hospitalization |
| مستخلص: | In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023-January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19-associated ED/UC encounters was 51% (95% CI = 47%-54%) during the first 7-59 days after an updated dose and 39% (95% CI = 33%-45%) during the 60-119 days after an updated dose. VE estimates against COVID-19-associated hospitalization from two CDC VE networks were 52% (95% CI = 47%-57%) and 43% (95% CI = 27%-56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19-associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023-2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccine. Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Steven Y. Chang reports consulting fees from PureTech Health and Kiniksa Pharmaceuticals, and participation on the data safety monitoring board for an unrelated, local study at Ronald Reagan UCLA Medical Center, outside the submitted work. Manjusha Gaglani reports serving as the Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics co-chair of the ID and Immunization Committee, outside the submitted work. Adit A. Ginde reports support from Biomeme and Seastar, outside the submitted work. Carlos G. Grijalva reports other funding from Merck, contracts from Syneos Health and the Food and Drug Administration, and grants from National Institutes of Health (NIH) and Agency for Health Care Research and Quality, outside the submitted work. Akram Khan reports grant funding from 4DMedical, Dompe Pharmaceuticals, Ely Lilly, and Roche Pharmaceuticals, outside the submitted work. Adam S. Lauring reports research support from the National Institute of Allergy and Infectious Diseases, Michigan Department of Health and Human Services, Burroughs Wellcome Fund, Flu Lab, and consulting fees from Roche, outside the submitted work. Christopher Mallow reports medical legal consulting, outside the submitted work. Emily T. Martin reports research funding from Merck, outside the submitted work. Ithan D. Peltan reports grant support from NIH, Intermountain Research and Medical Foundation, and Janssen Pharmaceuticals, and funding to his institution from Bluejay Diagnostics and Regeneron, outside the submitted work. Karthik Natarajan reports institutional support from NIH, Office of the Director, the National Center for Advancing Translational Sciences, and the National Heart, Lung, and Blood Institute. Brian E. Dixon reports Institutional support from NIH, National Library of Medicine in the form of a T15 training grant in biomedical informatics, salary support from the U.S. Department of Veterans Affairs, royalties from Elsevier, Inc. for a book on health information technology and from Springer Nature for a book on health information technology. Nicola P. Klein reports support from GSK, Merck, Pfizer, Sanofi Pasteur, and Seqirus for work unrelated to this report. No other potential conflicts of interest were disclosed. |
| References: | Euro Surveill. 2024 Jan;29(2):. (PMID: 38214083) Cell Host Microbe. 2024 Feb 10;:. (PMID: 38377995) Clin Infect Dis. 2022 Aug 24;75(1):e564-e571. (PMID: 35325923) Euro Surveill. 2024 Jan;29(1):. (PMID: 38179623) MMWR Morb Mortal Wkly Rep. 2024 Feb 01;73(4):77-83. (PMID: 38300853) MMWR Morb Mortal Wkly Rep. 2023 Oct 20;72(42):1140-1146. (PMID: 37856366) Lancet Infect Dis. 2024 Feb;24(2):e70-e72. (PMID: 38109919) Lancet Infect Dis. 2024 Feb;24(2):e73-e74. (PMID: 38190834) MMWR Morb Mortal Wkly Rep. 2023 May 26;72(21):579-588. (PMID: 37227984) |
| معلومات مُعتمدة: | R35 GM151147 United States GM NIGMS NIH HHS |
| فهرسة مساهمة: | Investigator: S Ghamande, Baylor Scott & White Health.; R Gottlieb, Baylor Scott & White Health.; T McNeal, Baylor Scott & White Health.; C Raver, Baylor Scott & White Health.; W Bender, Emory University.; L Fletcher, HealthPartners.; P Heaton, HealthPartners.; S Kane, HealthPartners.; C McEvoy, HealthPartners.; S Thapa, HealthPartners.; G Vazquez-Benitez, HealthPartners.; A Frosch, Hennepin County Medical Center.; LE Lamerato, Henry Ford Health.; M Ramesh, Henry Ford Health.; J Arnofer, Intermountain Healthcare.; H Ali; J Hopkins; B Crane, Kaiser Permanente Center for Health Research.; P Dandamudi, Kaiser Permanente Center for Health Research.; K Goddard, Kaiser Permanente Northern California.; J Hansen, Kaiser Permanente Northern California.; J Timbol, Kaiser Permanente Northern California.; O Zerbo, Kaiser Permanente Northern California.; K Allen, Regenstrief Institute.; T Duszynski, Regenstrief Institute.; W Fadel, Regenstrief Institute.; C Rogerson, Regenstrief Institute.; N Qadir, University of California, Los Angeles.; C Chavez, University of Colorado.; B Doyle, University of Colorado.; D Mayer, University of Colorado.; S Rao, University of Colorado.; C Rivas, University of Miami.; NJ Johnson, University of Washington.; A Baughman, Vanderbilt University Medical Center.; CT Lwin, Vanderbilt University Medical Center.; JP Rhoads, Vanderbilt University Medical Center.; KN Womack, Vanderbilt University Medical Center.; M Dunne, Westat.; A Ciesla, CDC.; J Mak, CDC.; M Najdowski, CDC.; C Ray, CDC. |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20240229 Date Completed: 20240304 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| مُعرف محوري في PubMed: | PMC10907041 |
| DOI: | 10.15585/mmwr.mm7308a5 |
| PMID: | 38421945 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1545-861X |
|---|---|
| DOI: | 10.15585/mmwr.mm7308a5 |